ADA and psoriasis: The keywords used in this research including “Psoriasis”, “biological treatment”, “TNF-alpha inhibitor”, “IL-12/IL-23 Inhibitors”, ” IL-17 Inhibitors”, “IL-23 Inhibitors”, “IL-23/IL-17 Inhibitors”, “Risankizumab”, “secukinumab”, “guselkumab”, “adalimumab”, “certolizumab”, “etanercept”, “ustekinumab”, “brodalumab”, “ixekizumab”, “tildrakizumab”, “Infliximab”, “methotrexate”, “briakinumab”, “golimumab”, “bimekizumab” and “ADA”.